A new study has found that Merck’s Wuhan coronavirus (COVID-19) drug molnupiravir, sold under the brand name Lagevrio, is causing new mutations of the virus in patients. But the Big Pharma company denies the accuracy of the study.
The new drug-linked mutations were discovered by American and British researchers. These new variants haven’t been studied closely enough to figure out if they are more immune-evasive or lethal, but their very existence has highlighted what some scientists say are potential risks in the wider use of the drug – the spread of even more contagious and health-threatening mutations of COVID-19.
Lagevrio works by mutating the genome of SARS-CoV-2 to prevent the virus from being able to replicate within a person’s body, reducing the chances it will cause severe illness. But scientists have warned from the very beginning that, by virtue of how the drug works, it could have the opposite effect and create new mutations that could easily bypass the immune protections people may have. (Related: Merck’s COVID antiviral drug molnupiravir a USELESS DUD, study finds.)
The researchers looked at some 13 million viral genome databases around the world. The mutations caused by Lagevrio were more commonly found in countries and regions where the drug was used, especially in the United States and Australia, where it was introduced early. But places like Canada and France, where the drug was not used, did not have the signature mutations in abundance.
“These effects are visible in these databases,” said Theo Sanderson, a geneticist from the Francis Crick Institute in London and the leader of the study. “It appears that people are being treated, some of them aren’t clearing their infections, and some are passing them on.”
“There’s always been this underlying concern that it could contribute to a problem generating new variants,” warned Jonathan Li, a virologist at Harvard Medical School and Brigham and Women’s Hospital in Boston. “This has largely been hypothetical, but this preprint validates a lot of those concerns.”
Expert: You’re playing with fire if you’re creating random mutations
Merck disputed the view that Lagevrio is causing the creation of problematic variants, with a spokesperson claiming no evidence has surfaced that any problematic mutations have spread to the public.
“There is no evidence to indicate that any antiviral agent has contributed to the emergence of circulating variants,” wrote spokesperson Robert Josephson in an email in response to questions raised regarding the study. “Based on available data, we do not believe that Lagevrio (molnupiravir) is likely to contribute to the development of new, meaningful coronavirus variants.”
Josephson noted that the study authors made a broad, unsubstantiated assumption that the mutations are associated with molnupiravir treatment but do not provide any direct proof that the mutations arose in patients who took Lagevrio.
The spokesperson claimed that the researchers drew their conclusions from “circumstantial associations between viral sequence origin and timeframe of sequence collection in countries where molnupiravir is available.”
Ryan Hisner, an independent researcher who helped write the study, noted that the risk of drug-linked mutations is far too great to continue using Lagevrio and the U.S. should consider discontinuing its use.
“It’s a very distressing situation,” said Michael Lin, an antiviral drug researcher from Stanford University who was consulted on the study. “There’s no evidence that any of these mutants is worse in any way – not yet – but it’s well agreed that you’re playing with fire if you’re creating random mutations and hoping nothing bad will come of it.”
For more on the latest activities of Big Pharma companies, visit BigPharmaNews.com.
Watch this clip from InfoWars as host Harrison Smith talks about how a top virologist believes the post-vaccine omicron variant of COVID-19 could have been created by Merck’s antiviral COVID-19 pill, molnupiravir.
This video is from the InfoWars channel on Brighteon.com.
More related stories:
- Merck’s new COVID pill linked to virus mutations, study finds.
- Merck and Pfizer’s “anti-COVID” pills are just another profiteering scam to exploit COVID hysteria.
- Merck’s new “miracle” COVID drug found to cause cancerous mutations in hamster experiments.
- Merck admits COVID pills are not nearly as effective as advertised.
- Merck gouges Americans by charging “new” federally financed COVID pill that’s a rip-off of ivermectin 40 TIMES what it costs to make.
Sources include:
Bypass Big Tech Censors
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.